AACHEN, Germany, December 5, 2017 /PRNewswire/ —
The Grünenthal Group announced today that Nucynta® (tapentadol) will be commercialized in the U.S. territory by Collegium Pharmaceutical, Inc., instead of Depomed, Inc., from 2018 onwards.
In recent months, Depomed has been…
